EverPoint Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

EverPoint Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.16M	Buy	+45,934	New	+$1.03M	0.02%	364
2016 Q3	–	Sell	-225,000	Closed	-$4.58M	–	497
2016 Q2	$4.58M	Sell	225,000 -105,000	-32%	-$1.86M	0.09%	236
2016 Q1	$5.03M	Buy	330,000 +80,000	+32%	+$1.04M	0.1%	223
2015 Q4	$3.36M	Buy	+250,000	New	+$3.87M	0.07%	321

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EverPoint Asset Management's SUPN Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q4 2016: 45,934 shares worth $1.16M. The stake represents 0.02% of the portfolio and ranks #364 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in SUPN as recently as Q2 2016.

EverPoint Asset Management first reported a position in SUPN in Q4 2015 and has held it in 4 quarters since. The position peaked at $5.03M in Q1 2016. 234 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

EverPoint Asset Management held 45,934 shares of Supernus Pharmaceuticals worth $1.16M as of Q4 2016.
Supernus Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
Supernus Pharmaceuticals made up 0.02% of EverPoint Asset Management's portfolio in Q4 2016, its #364 holding.
EverPoint Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 4 quarters since.
EverPoint Asset Management's Supernus Pharmaceuticals position peaked at $5.03M in Q1 2016.
234 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.